Prolonged Isolation May Be Detrimental for Elderly Cancer Patients During the Pandemic
With Capucine Baldini, Gustave Roussy, Villejuif, France
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Fewer Cancer Diagnoses During COVID-19 Outbreak in the Netherlands
Multifactorial reasons involving patients, general practitioners and the healthcare system
FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian Cancer
FDA also approved the Myriad myChoice® CDx as a companion diagnostic for olaparib
FDA Approves Selpercatinib for Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Efficacy was evaluated in a multicentre, open-label, multi-cohort LIBRETTO-001 trial
Lower Antibodies Rate in Cancer Patients After Symptomatic COVID-19 Than In Healthcare Workers
Antibodies more often undetectable in patients who received anticancer treatment in the month prior to testing
EMA Does Not Recommend Extending the Use of Pembrolizumab
Application concerned first-line treatment in patients with NSCLC and PD-L1 scores between 1 and 49%
FDA Approves Daratumumab and Hyaluronidase-fihj for Multiple Myeloma
This new product allows for subcutaneous dosing of daratumumab
Early Melanoma Recurrence to Adjuvant Anti-PD-1 Therapy
Findings from 16 centres worldwide
FDA Grants Accelerated Approval to Capmatinib for Metastatic NSCLC
FDA also approved a companion diagnostic for capmatinib
A Proactive and Multipronged Approach as COVID-19 Response in India
Balancing pandemic control with providing continued cancer care
EMA Recommends Extension of Indications for Encorafenib
It is indicated in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation
FDA Approves Niraparib for First-Line Maintenance Treatment of Advanced Ovarian Cancer
An FDA-approved companion diagnostic is not required to initiate treatment with niraparib for this indication